RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement

Conclusion

The findings of the SELECT-EARLY study indicate that, compared with patients receiving methotrexate, patients receiving either dose of upadacitinib monotherapy experience significant improvements in clinical, radiographic and patient-reported outcomes.

Refer to the full study for all source material.

Excerpted and adapted from:

van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-highly active rheumatoid arthritis: A multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020 Oct;72(10):1607–1620.